IO Biotech appoints Dr Peter Hirth as Chairman of the Board

Oct 4, 2016

Copenhagen, Denmark – October 4, 2016: IO Biotech today announced that industry veteran Dr Peter Hirth will succeed Dr Hans Schambye as Chairman of the Board of Directors. IO Biotech develops novel therapeutic immuno-oncology vaccines targeting immune check point inhibitory targets to treat cancer.

Other news

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

November 9, 2021
IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

September 14, 2021
back to news overview